Study on Ultramicronized PEA for Sensory Function in Children with ASD
A clinical trial is evaluating the efficacy of ultramicronized palmitoylethanolamide (umPEA) in improving sensory function in children with Autism Spectrum Disorder compared to standard treatment.
Phase III
Neurology / Autism Spectrum Disorder
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Strategic implication
Portfolio teams should consider the potential of umPEA as a complementary therapy in ASD, which may enhance their offerings in pediatric neurology.
Why it matters
The ongoing clinical trial of ultramicronized palmitoylethanolamide (umPEA) for sensory function in children with Autism Spectrum Disorder could redefine treatment strategies in this area. If successful, umPEA may complement existing therapies and enhance market offerings in pediatric neurology.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the trial results and any subsequent publications regarding the efficacy of umPEA in improving sensory symptoms in ASD.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.